BCAT1 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder

Histopathology

Volumn 68, Issue 4, 2016, Pages 520-532

  Chang, I Wei ^a   Wu, Wen Jen ^b,c,d,e,f   Wang, Yu Hui ^g   Wu, Ting Feng ^h   Liang, Peir In ^d   He, Hong Lin ^a   Yeh, Bi Wen ^b,c,d,e,f   Li, Chien Feng ^d,f,h,i,j  

^a I SHOU UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

ⁱ CHI MEI MEDICAL CENTER   (Taiwan)

^j NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

more..

Author keywords

BCAT1; Branched chain amino acid transaminase 1; Upper urinary tract; Urinary bladder; Urothelial carcinoma

Indexed keywords

BRANCHED CHAIN AMINO ACID; BRANCHED CHAIN AMINO ACID TRANSAMINASE 1; UNCLASSIFIED DRUG; AMINOTRANSFERASE; BCAT1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER PROGNOSIS; CELL INVASION; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MIDDLE AGED; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; TUMOR LOCALIZATION; UPREGULATION; URINARY TRACT CARCINOMA; BIOSYNTHESIS; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; URINARY TRACT TUMOR; WESTERN BLOTTING;

AGED; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; TRANSAMINASES; UP-REGULATION; UROLOGIC NEOPLASMS;

EID: 84957942575     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12778     Document Type: Article

References (46)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World health organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC) Press, 2004.
2. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J. Urol. 2009; 27; 289-293.
3. Roupret M, Zigeuner R, Palou J et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur. Urol. 2011; 59; 584-594.
4. McLaughlin JK, Silverman DT, Hsing AW et al. Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res. 1992; 52; 254-257.
5. Pommer W, Bronder E, Klimpel A, Helmert U, Greiser E, Molzahn M. Urothelial cancer at different tumour sites: role of smoking and habitual intake of analgesics and laxatives. Results of the Berlin Urothelial Cancer Study. Nephrol. Dial. Transplant. 1999; 14; 2892-2897.
6. Shinka T, Miyai M, Sawada Y, Inagaki T, Okawa T. Factors affecting the occurrence of urothelial tumors in dye workers exposed to aromatic amines. Int. J. Urol. 1995; 2; 243-248.
7. Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008; 74; 158-169.
8. Dragicevic D, Djokic M, Pekmezovic T et al. Survival of patients with transitional cell carcinoma of the ureter and renal pelvis in balkan endemic nephropathy and non-endemic areas of Serbia. BJU Int. 2007; 99; 1357-1362.
9. Laing C, Hamour S, Sheaff M, Miller R, Woolfson R. Chinese herbal uropathy and nephropathy. Lancet 2006; 368; 338.
10. Stewart JH, Hobbs JB, McCredie MR. Morphologic evidence that analgesic-induced kidney pathology contributes to the progression of tumors of the renal pelvis. Cancer 1999; 86; 1576-1582.
11. Catto JW, Azzouzi AR, Rehman I et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol. 2005; 23; 2903-2910.
12. Zhang Z, Furge KA, Yang XJ, Teh BT, Hansel DE. Comparative gene expression profiling analysis of urothelial carcinoma of the renal pelvis and bladder. BMC Med. Genomics 2010; 3; 58.
13. Catto JW, Yates DR, Rehman I et al. Behavior of urothelial carcinoma with respect to anatomical location. J. Urol. 2007; 177; 1715-1720.
14. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat. Rev. Cancer 2011; 11; 85-95.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144; 646-674.
16. Smerc A, Sodja E, Legisa M. Posttranslational modification of 6-phosphofructo-1-kinase as an important feature of cancer metabolism. PLoS ONE 2011; 6; e19645.
17. Barretina J, Taylor BS, Banerji S et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 2010; 42; 715-721.
18. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat. Rev. Cancer 2010; 10; 267-277.
19. Huang HY, Wu WR, Wang YH et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin. Cancer Res. 2013; 19; 2861-2872.
20. Lan J, Tai HC, Lee SW, Chen TJ, Huang HY, Li CF. Deficiency in expression and epigenetic DNA methylation of ASS1 gene in nasopharyngeal carcinoma: negative prognostic impact and therapeutic relevance. Tumour Biol. 2014; 35; 161-169.
21. Lin CY, Sheu MJ, Li CF et al. Deficiency in asparagine synthetase expression in rectal cancers receiving concurrent chemoradiotherapy: negative prognostic impact and therapeutic relevance. Tumour Biol. 2014; 35; 6823-6830.
22. Ichihara A, Koyama E. Transaminase of branched chain amino acids. I. Branched chain amino acids-alpha-ketoglutarate transaminase. J. Biochem. 1966; 59; 160-169.
23. Taylor RT, Jenkins WT. Leucine aminotransferase. II. Purification and characterization. J. Biol. Chem. 1966; 241; 4396-4405.
24. Tönjes M, Barbus S, Park YJ et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nat. Med. 2013; 19; 901-908.
25. Zhang EY, Cristofanilli M, Robertson F et al. Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. J. Proteome Res. 2013; 12; 2805-2817.
26. Zhou W, Feng X, Ren C et al. Over-expression of BCAT1, a c-Myc target gene, induces cell proliferation, migration and invasion in nasopharyngeal carcinoma. Mol. Cancer. 2013; 12; 53.
27. Huang WW, Huang HY, Liao AC et al. Primary urothelial carcinoma of the upper tract: important clinicopathological factors predicting bladder recurrence after surgical resection. Pathol. Int. 2009; 59; 642-649.
28. Wu LC, Chen LT, Tsai YJ et al. Alpha-methylacyl coenzyme A racemase overexpression in gallbladder carcinoma confers an independent prognostic indicator. J. Clin. Pathol. 2012; 65; 309-314.
29. Budwit-Novotny DA, McCarty KS, Cox EB et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986; 46; 5419-5425.
30. McClelland RA, Finlay P, Walker KJ et al. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res. 1990; 50; 3545-3550.
31. Rodríguez-Alonso A, Pita-Fernández S, González-Carreró J, Nogueira-March JL. Multivariate analysis of survival, recurrence, progression and development of mestastasis in T1 and T2a transitional cell bladder carcinoma. Cancer 2002; 94; 1677-1684.
32. Hansel DE, Amin MB, Comperat E et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur. Urol. 2013; 63; 321-332.
33. Brosnan JT, Brosnan ME. Branched-chain amino acids: enzyme and substrate regulation. J. Nutr. 2006; 136; 207S-211S.
34. Shimomura Y, Murakami T, Nakai N, Nagasaki M, Harris RA. Exercise promotes BCAA catabolism: effects of BCAA supplementation on skeletal muscle during exercise. J. Nutr. 2004; 134; 1583S-1587S.
35. Creighton T. Proteins: structure and molecular properties. New York, NY: W. H. Freeman, 1993.
36. Chou PY, Fasman GD. Structural and functional role of leucine residues in proteins. J. Mol. Biol. 1973; 74; 263-281.
37. Suryawan A, Hawes JW, Harris RA, Shimomura Y, Jenkins AE, Hutson SM. A molecular model of human branched-chain amino acid metabolism. Am. J. Clin. Nutr. 1998; 68; 72-81.
38. Schuldiner O, Eden A, Ben-Yosef T, Yanuka O, Simchen G, Benvenisty N. ECA39, a conserved gene regulated by c-Myc in mice, is involved in G1/S cell cycle regulation in yeast. Proc. Natl Acad. Sci. USA 1996; 93; 7143-7148.
39. Ben-Yosef T, Yanuka O, Halle D, Benvenisty N. Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene 1998; 17; 165-171.
40. Rodriguez S, Jafer O, Goker H et al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. Oncogene 2003; 22; 1880-1891.
41. Yoshikawa R, Yanagi H, Shen CS et al. ECA39 is a novel distant metastasis-related biomarker in colorectal cancer. World J. Gastroenterol. 2006; 12; 5884-5889.
42. Zhou W, Feng X, Li H et al. Functional evidence for a nasopharyngeal carcinoma-related gene BCAT1 located at 12p12. Oncol. Res. 2007; 16; 405-413.
43. de Bont JM, Kros JM, Passier MM et al. Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. Neuro Oncol. 2008; 10; 648-660.
44. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, Lee HP. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol. Res. 2009; 18; 47-56.
45. Li CF, Wu WJ, Wu WR et al. The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma. Oncotarget 2015; 6; 9220-9239.
46. Chang IW, Lin VC, He HL et al. CDCA5 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder. Am. J. Transl. Res. 2015; 7; 710-722.